

### **REMARKS**

In the Restriction Requirement, when identifying the claims of Groups I – VI, the examiner refers to the claims as originally filed, i.e., Claims 1-156. However, in the Preliminary Amendment mailed March 15, 2005, Applicants amended the claims so as to delete the dependent claims originally filed, leaving only the independent claims. The two independent claims that correspond to Group V identified in the Restriction Requirement are Claims 92 and 127.

As requested by the examiner in the Restriction Requirement, independent Claims 92 and 127 have been amended to specify the SEQ ID NO of the peptide elected by Applicants. More specifically, the independent claims have been amended to specify SEQ ID NO: 4, which corresponds to the elected peptide ARRQAV.

In addition, Applicants have added as new claims some of the dependent claims identified by the examiner as belonging to Group V. As stated above, the dependent claims were set forth in the application as originally filed, but then deleted in the first Preliminary Amendment. More specifically, Claims 99 -101 as originally filed have been added herein as new Claims 158-160. In addition, Claims 134 – 138 as originally filed have been added herein as new Claims 161-165.

It is now believed that this application is in condition for further consideration and examination. If resolution of any remaining issues are required prior to the examination of the application, it is respectfully requested that the examiner contact Applicants' attorney at the telephone number provided below.

Respectfully submitted,

/james f. harrington/  
James F. Harrington  
Registration No. 44,741  
Attorney for Applicants

HOFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791  
(516) 822-3550  
JFH:jp